This page/content is for Great Britain healthcare professionals only.
Pluvicto® is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.1
Pluvicto is a PSMA-targeted radioligand therapy (RLT) that delivers DNA-breaking radiation directly to PSMA-positive bone, nodal, and visceral metastases.1–3
Here, you can access relevant information on Pluvicto and a range of engaging resources to solidify your knowledge. Click the links below to explore Pluvicto's mechanism of action, dosing and administration and key efficacy and safety data from the VISION study.
Quick links
177Lu, lutetium; AR, androgen receptor; DNA, deoxyribonucleic acid; mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen; RLT, radioligand therapy.
References:
- Pluvicto® Great Britain Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/13965/smpc [Accessed March 2023].
- Benešová M, et al. J Nucl Med 2015;56(6):914–920.
- Fendler WP, et al. J Nucl Med 2017;58(11):1786–1792.